Viewing Study NCT06505304



Ignite Creation Date: 2024-10-26 @ 3:35 PM
Last Modification Date: 2024-10-26 @ 3:35 PM
Study NCT ID: NCT06505304
Status: RECRUITING
Last Update Posted: None
First Post: 2024-07-10

Brief Title: AI-enabled Endoscopic Prediction of Post-operative Recurrence in Crohns Disease
Sponsor: None
Organization: None

Study Overview

Official Title: Endoscopic Multimodal Assessment Using Advanced Imaging Integrated AI to Predict Recurrence in pOSt-oPerativE CRohns Disease - PROSPER Study
Status: RECRUITING
Status Verified Date: 2024-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: PROSPER
Brief Summary: This is a multicentre prospective international observational study This study aims to introduce a novel multidimensional approach to precision imaging enabling the identification and stratification of high-risk patients who can potentially benefit from early treatments to halt the progression of Crohns disease CD The investigators will develop a novel endoscopic assessment system using endoscopic enhanced imaging EEI to evaluate early post-surgical changes and predict post-operative CD recurrence POCr By integrating with immune marker profiling clinical data and AI assessment of EEI and histology the investigators further plan to improve risk stratification and reduce interobserver variability
Detailed Description: Background

Up to 70 of Crohns disease CD patients will undergo a surgical resection in their lifetime However surgery is non-curative since 50 of patients have a recurrence and about one-third need repeat surgery The tools currently used to assess CD recurrences such as faecal calprotectin FCP cross-sectional imaging small bowel ultrasound MRI scan and conventional endoscopy have a limited role in predicting early Post-Operative CD recurrence POCr Distinguishing inflammatory disease recurrence from post-surgical ischemic or suture-related alterations poses a significant challenge Endoscopic Enhanced imaging EEI techniques like virtual electronic chromoendoscopy VCE and biopsy-like probe-based confocal laser endomicroscopy pCLE combined with artificial intelligence can improve the detection of mucosalvascular changes before major alterations become evident VCE is available simply by switching a button The pCLE probe will be passed through the endoscope channel like a biopsy forceps enabling real-time histology-like images of the intestines lining and the gut barrier

Study summary

This is a multicentre prospective international observational study This study aims to introduce a novel multidimensional approach to precision imaging enabling the identification and stratification of high-risk patients who can potentially benefit from early treatments to halt the progression of CD

The investigators will develop a novel endoscopic assessment system using EEI to evaluate early post-surgical changes and predict POCr By integrating with immune marker profiling clinical data and AI assessment of EEI and histology the investigators further plan to improve risk stratification and reduce interobserver variability A detailed exploratory analysis will only be done in a cohort of patients in Ireland The correlation between the new scoring system and established endoscopic and histologic scores cross-sectional imaging and non-invasive markers of inflammation will be evaluated A multimodal machine learning model will be developed on EEI videos histology clinical data and immune molecular analysis to stratify patients risk of early recurrence and long-term outcomes The study will be divided into three phases

In the first phase descriptor criteria for the assessment of post-operative Crohns Disease will be defined Gastroenterologists experienced in IBD endoscopy will review images and videos from an existing library showing the different grade of inflammation of the modified Rutgeerts score These will be used for a stepwise discussion A round table discussion using modified Delphi method will be conducted to ensure equal participation and identify the best component descriptors of endoscopic recurrence of CD The components that achieved 100 consensus will be selected and the most important endoscopy predictive variables will be confirmed by using a machine learning technique Finally a new endoscopic score will be generated Further the investigators will first validate the new endoscopic score using the first 30 consecutive VCE and pCLE videos of POCr patients recruited in the multicenter PROSPER study A structured consensus will be conducted with experts in Inflammatory Bowel Disease endoscopy and histology to define the endoscopic findings of mucosal vascular and intestinal barrier function Subsequently the investigators will prospectively validate the score in a large cohort of POCr patients enrolled in the PROSPER study and assess the diagnostic accuracy of the new scoring system in predicting post-surgical recurrence Clinical information blood saliva stool and bowel specimens will be taken Cross-sectional imaging magnetic resonance imaging -MRI- intestinal ultrasound -IUS- endoscopy VCE and pCLE in equipped centres will be performed according to stool calprotectin 3 months after surgery Patients will be followed up for 24 months and the results of the follow-up colonoscopy performed as standard of care within 18 months from the index colonoscopy will be collected
In the second phase the investigators will externally validate and reproduce the new scoring system by gastroenterologists using a computerized training module
In the third phase an advanced computer-aided quantitative analysis of videos images from VCE and pCLE and digital histology will be developed and validated to enhance the prediction of POCr Additionally further machine learning models will be developed utilizing comprehensive data from blood stool cross-sectional imaging endoscopy histology immune markers and OMICs to predict POCr and long-term outcomes

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None